137 related articles for article (PubMed ID: 12614625)
21. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
[TBL] [Abstract][Full Text] [Related]
22. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.
Ruas M; Brookes S; McDonald NQ; Peters G
Oncogene; 1999 Sep; 18(39):5423-34. PubMed ID: 10498896
[TBL] [Abstract][Full Text] [Related]
23. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
24. Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of p34(SEI-1) and p16(INK4A).
Li J; Muscarella P; Joo SH; Knobloch TJ; Melvin WS; Weghorst CM; Tsai MD
Biochemistry; 2005 Oct; 44(40):13246-56. PubMed ID: 16201750
[TBL] [Abstract][Full Text] [Related]
25. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb.
Li J; Tsai MD
Biochemistry; 2002 Mar; 41(12):3977-83. PubMed ID: 11900540
[TBL] [Abstract][Full Text] [Related]
26. Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A.
Li J; Byeon IJ; Ericson K; Poi MJ; O'Maille P; Selby T; Tsai MD
Biochemistry; 1999 Mar; 38(10):2930-40. PubMed ID: 10074345
[TBL] [Abstract][Full Text] [Related]
27. p16(INK4a) Peptide mimetics identified via virtual screening.
Klein MA; Mayo KH; Kratzke RA
Bioorg Med Chem Lett; 2010 Jan; 20(1):403-5. PubMed ID: 19914831
[TBL] [Abstract][Full Text] [Related]
28. Analysis of p16INK4a and its interaction with CDK4.
Yang R; Serrano M; Slater J; Leung E; Koeffler HP
Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
[TBL] [Abstract][Full Text] [Related]
29. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
Russo AA; Tong L; Lee JO; Jeffrey PD; Pavletich NP
Nature; 1998 Sep; 395(6699):237-43. PubMed ID: 9751050
[TBL] [Abstract][Full Text] [Related]
30. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4.
Zhao Q; Boschelli F; Caplan AJ; Arndt KT
J Biol Chem; 2004 Mar; 279(13):12560-4. PubMed ID: 14701845
[TBL] [Abstract][Full Text] [Related]
31. Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors.
Mori N; Yang R; Kawamata N; Miller CW; Mizoguchi H; Koeffler HP
Int J Hematol; 2003 Apr; 77(3):259-62. PubMed ID: 12731669
[TBL] [Abstract][Full Text] [Related]
32. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
33. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
Zou X; Ray D; Aziyu A; Christov K; Boiko AD; Gudkov AV; Kiyokawa H
Genes Dev; 2002 Nov; 16(22):2923-34. PubMed ID: 12435633
[TBL] [Abstract][Full Text] [Related]
34. The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage.
Al-Khalaf HH; Mohideen P; Nallar SC; Kalvakolanu DV; Aboussekhra A
J Biol Chem; 2013 Dec; 288(49):35511-25. PubMed ID: 24163379
[TBL] [Abstract][Full Text] [Related]
35. Structure of the cyclin-dependent kinase inhibitor p19Ink4d.
Luh FY; Archer SJ; Domaille PJ; Smith BO; Owen D; Brotherton DH; Raine AR; Xu X; Brizuela L; Brenner SL; Laue ED
Nature; 1997 Oct; 389(6654):999-1003. PubMed ID: 9353127
[TBL] [Abstract][Full Text] [Related]
36. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
37. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
39. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity.
Li J; Li H; Tsai MD
Biochemistry; 2003 Jun; 42(22):6921-8. PubMed ID: 12779347
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
